{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:57:50Z","timestamp":1760029070929,"version":"3.44.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T00:00:00Z","timestamp":1737763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T00:00:00Z","timestamp":1737763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82160707, 82060677 and 81603188"],"award-info":[{"award-number":["82160707, 82060677 and 81603188"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","award":["20202ACB216005"],"award-info":[{"award-number":["20202ACB216005"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Natural Science Foundation for Academic and Technical Leaders of Jiangxi Province","award":["20204BCJL23053"],"award-info":[{"award-number":["20204BCJL23053"]}]},{"DOI":"10.13039\/501100019079","name":"Postdoctoral Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","award":["2017KY24"],"award-info":[{"award-number":["2017KY24"]}],"id":[{"id":"10.13039\/501100019079","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s00210-024-03768-3","type":"journal-article","created":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T00:35:01Z","timestamp":1737765301000},"page":"8773-8783","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Evaluation of drug-drug interaction between rosuvastatin and tacrolimus and the risk of hepatic injury in rats"],"prefix":"10.1007","volume":"398","author":[{"given":"Lulu","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Ning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiake","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingcheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xijing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohui","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,25]]},"reference":[{"issue":"9","key":"3768_CR1","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1124\/dmd.110.032268","volume":"38","author":"R Amundsen","year":"2010","unstructured":"Amundsen R, Christensen H, Zabihyan B et al (2010) Cyclosporine A, but not tacrolimus, shows relevant inhibition of organic anion-transporting protein 1B1-mediated transport of atorvastatin. Drug Metab Dispos 38(9):1499\u20131504","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"3768_CR2","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2165\/00003495-200363040-00003","volume":"63","author":"A Asberg","year":"2003","unstructured":"Asberg A (2003) Interactions between cyclosporine and lipid-lowering drugs: implications for organ transplant recipients. Drugs 63(4):367\u2013378","journal-title":"Drugs"},{"key":"3768_CR3","unstructured":"Astellas Pharma Co. PROGRAF (tacrolimus) [package insert]. Rxlist. https:\/\/www.rxlist.com Updated Oct 3,2023. Accessed 20 May 2024"},{"key":"3768_CR4","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1002\/ptr.4894","volume":"27","author":"S Basu","year":"2013","unstructured":"Basu S, Jana S, Patel VB, Patel H (2013) Effects of piperine, cinnamic acid and gallic acid on rosuvastatin pharmacokinetics in rats. Phytother Res 27:1548\u20131556","journal-title":"Phytother Res"},{"issue":"2","key":"3768_CR5","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.pcad.2016.08.001","volume":"59","author":"LB Benes","year":"2016","unstructured":"Benes LB, Bassi NS, Davidson MH (2016) The risk of hepatotoxicity, new onset diabetes and rhabdomyolysis in the era of high-intensity statin therapy: does statin type matter? Prog Cardiovasc Dis 59(2):145\u2013152","journal-title":"Prog Cardiovasc Dis"},{"issue":"3","key":"3768_CR6","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/FTD.0000000000000640","volume":"41","author":"M Brunet","year":"2019","unstructured":"Brunet M, van Gelder T, \u00c5sberg A et al (2019) Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report. Ther Drug Monit 41(3):261\u2013307","journal-title":"Ther Drug Monit"},{"key":"3768_CR7","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.2165\/00003495-200262140-00008","volume":"62","author":"CI Carswell","year":"2002","unstructured":"Carswell CI, Plosker GL, Jarvis B (2002) Rosuvastatin Drugs 62:2075\u20132087","journal-title":"Rosuvastatin Drugs"},{"key":"3768_CR8","unstructured":"Chen W, Zhang L, Zhang Y, et al (2022) Expert consensus on individualized tacrolimus therapy for solid organ transplantation [J]. Practical Organ Transplantation Electronic Journal 10(04):301\u2013308"},{"issue":"3","key":"3768_CR9","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1007\/s12072-017-9786-1","volume":"11","author":"KKW Chu","year":"2017","unstructured":"Chu KKW, Chan SC, Sin SL et al (2017) Lipid profiles of donors and recipients of liver transplant: like father like son. Hepatol Int 11(3):300\u2013305","journal-title":"Hepatol Int"},{"issue":"8","key":"3768_CR10","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.healun.2010.05.034","volume":"29","author":"MR Costanzo","year":"2010","unstructured":"Costanzo MR, Dipchand A, Starling R et al (2010) International Society of Heart and Lung Transplantation Guidelines. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 29(8):914\u201356","journal-title":"J Heart Lung Transplant."},{"issue":"9","key":"3768_CR11","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1124\/dmd.121.000430","volume":"49","author":"F Deng","year":"2021","unstructured":"Deng F, Tuomi SK, Neuvonen M et al (2021) Comparative hepatic and intestinal efflux transport of statins. Drug Metab Dispos 49(9):750\u2013759","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"3768_CR12","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1124\/dmd.115.066795","volume":"44","author":"R Elsby","year":"2016","unstructured":"Elsby R, Martin P, Surry D et al (2016) Solitary inhibition of the breast cancer resistance protein efflux transporter results in a clinically significant drug-drug interaction with rosuvastatin by causing up to a 2-fold increase in statin exposure. Drug Metab Dispos 44(3):398\u2013408","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"3768_CR13","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1124\/dmd.113.054932","volume":"42","author":"G Englund","year":"2014","unstructured":"Englund G, Lundquist P, Skogastierna C et al (2014) Cytochrome p450 inhibitory properties of common efflux transporter inhibitors. Drug Metab Dispos 42(3):441\u2013447","journal-title":"Drug Metab Dispos"},{"key":"3768_CR14","doi-asserted-by":"publisher","first-page":"6613786","DOI":"10.1155\/2021\/6613786","volume":"2021","author":"N Fatima","year":"2021","unstructured":"Fatima N, Sheikh N, Satoskar AR et al (2021) Effect of short-term tacrolimus exposure on rat liver: an insight into serum antioxidant status, liver lipid peroxidation, and inflammation. Mediators Inflamm 2021:6613786","journal-title":"Mediators Inflamm"},{"issue":"3","key":"3768_CR15","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1007\/s00280-005-0173-6","volume":"58","author":"A Gupta","year":"2006","unstructured":"Gupta A, Dai Y, Vethanayagam RR et al (2006) Cyclosporine A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. Cancer Chemother Pharmacol 58(3):374\u2013383","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10","key":"3768_CR16","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1007\/s11095-021-03109-6","volume":"38","author":"N Hanke","year":"2021","unstructured":"Hanke N, G\u00f3mez-Mantilla JD, Ishiguro N et al (2021) Physiologically based pharmacokinetic modeling of rosuvastatin to predict transporter-mediated drug-drug interactions. Pharm Res 38(10):1645\u20131661","journal-title":"Pharm Res"},{"issue":"8","key":"3768_CR17","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1021\/mp500027c","volume":"11","author":"J He","year":"2014","unstructured":"He J, Yu Y, Prasad B, Link J, Miyaoka RS, Chen X, Unadkat JD (2014) PET imaging of Oatp-mediated hepatobiliary transport of [(11)C] rosuvastatin in the rat. Mol Pharm 11(8):2745\u20132754","journal-title":"Mol Pharm"},{"issue":"2","key":"3768_CR18","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/jphp.13026","volume":"71","author":"J He","year":"2019","unstructured":"He J, Zhang G, Zhang Q et al (2019) Evaluation of inhaled recombinant human insulin dry powders: pharmacokinetics, pharmacodynamics and 14-day inhalation. J Pharm Pharmacol 71(2):176\u2013184","journal-title":"J Pharm Pharmacol"},{"issue":"1","key":"3768_CR19","doi-asserted-by":"publisher","first-page":"e13454","DOI":"10.1111\/ctr.13454","volume":"33","author":"A Heeney Stephanie","year":"2019","unstructured":"Heeney Stephanie A, Tjugum Shelby L, Corkish Morgan E et al (2019) Safety and tolerability of high-intensity statin therapy in heart transplant patients receiving immunosuppression with tacrolimus. Clin Transplant 33(1):e13454","journal-title":"Clin Transplant"},{"issue":"7","key":"3768_CR20","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1124\/dmd.106.009290","volume":"34","author":"M Hirano","year":"2006","unstructured":"Hirano M, Maeda K, Shitara Y, Sugiyama Y (2006) Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos 34(7):1229\u20131236","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"3768_CR21","doi-asserted-by":"publisher","first-page":"327","DOI":"10.3109\/00498254.2011.625452","volume":"42","author":"M Hobbs","year":"2012","unstructured":"Hobbs M, Parker C, Birch H, Kenworthy K (2012) Understanding the interplay of drug transporters involved in the disposition of rosuvastatin in the isolated perfused rat liver using a physiologically-based pharmacokinetic model. Xenobiotica 42(4):327\u2013338","journal-title":"Xenobiotica"},{"issue":"2","key":"3768_CR22","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S0021-9150(01)00438-5","volume":"158","author":"N Ichimaru","year":"2001","unstructured":"Ichimaru N, Takahara S, Kokado Y et al (2001) Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus. Atherosclerosis 158(2):417\u2013423","journal-title":"Atherosclerosis"},{"issue":"5","key":"3768_CR23","doi-asserted-by":"publisher","first-page":"263","DOI":"10.14740\/gr1212","volume":"12","author":"S Jamil","year":"2019","unstructured":"Jamil S, Vivek L, Nikolaos P et al (2019) Acute liver injury in a patient treated with rosuvastatin: a rare adverse effect. Gastroenterology Res 12(5):263\u2013266","journal-title":"Gastroenterology Res"},{"issue":"2","key":"3768_CR24","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.tiv.2009.10.009","volume":"24","author":"K Jemnitz","year":"2010","unstructured":"Jemnitz K, Veres Z, Tugyi R et al (2010) Biliary efflux transporters involved in the clearance of rosuvastatin in sandwich culture of primary rat hepatocytes. Toxicol in Vitro 24(2):605\u2013610","journal-title":"Toxicol in Vitro"},{"issue":"5","key":"3768_CR25","doi-asserted-by":"publisher","first-page":"351","DOI":"10.5001\/omj.2014.93","volume":"29","author":"J Jose","year":"2014","unstructured":"Jose J, Al-Tamimi FA, Helal MM et al (2014) Statin associated hepatic adverse effects: a retrospective review from a regional hospital in sultanate of oman. Oman Med J 29(5):351\u2013357","journal-title":"Oman Med J"},{"issue":"7\u20138","key":"3768_CR26","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1159\/000516240","volume":"106","author":"CV Jota Baptista","year":"2021","unstructured":"Jota Baptista CV, Faustino-Rocha AI, Oliveira PA (2021) Animal models in pharmacology: a brief history awarding the Nobel prizes for physiology or medicine. Pharmacology 106(7\u20138):356\u2013368","journal-title":"Pharmacology"},{"issue":"9","key":"3768_CR27","doi-asserted-by":"publisher","first-page":"745","DOI":"10.2147\/DDDT.S76942","volume":"2","author":"JA Jung","year":"2015","unstructured":"Jung JA, Lee SY, Kim JR et al (2015) A pharmacokinetic and pharmacodynamic drug interaction between rosuvastatin and valsartan in healthy subjects. Drug des Devel Ther 2(9):745\u2013752","journal-title":"Drug des Devel Ther"},{"key":"3768_CR28","doi-asserted-by":"crossref","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group (2009) KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 9(Suppl 3): 1\u2013155","DOI":"10.1111\/j.1600-6143.2009.02834.x"},{"issue":"11","key":"3768_CR29","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.2147\/DDDT.S146863","volume":"5","author":"CH Kim","year":"2017","unstructured":"Kim CH, An H, Kim SH, Shin D (2017) Pharmacokinetic and pharmacodynamic interaction between ezetimibe and rosuvastatin in healthy male subjects. Drug des Devel Ther 5(11):3461\u20133469","journal-title":"Drug des Devel Ther"},{"issue":"1","key":"3768_CR30","doi-asserted-by":"publisher","first-page":"19410","DOI":"10.1038\/s41598-019-55562-4","volume":"9","author":"Y Kim","year":"2019","unstructured":"Kim Y, Yoon S, Choi Y et al (2019) Influence of OATP1B1 and BCRP polymorphisms on the pharmacokinetics and pharmacodynamics of rosuvastatin in elderly and young Korean subjects. Sci Rep 9(1):19410","journal-title":"Sci Rep"},{"issue":"3","key":"3768_CR31","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1177\/1074248408318628","volume":"13","author":"MS Kostapanos","year":"2008","unstructured":"Kostapanos MS, Milionis HJ, Elisaf MS (2008) An overview of the extra-lipid effects of rosuvastatin. J Cardiovasc Pharmacol Ther 13(3):157\u2013174","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"2","key":"3768_CR32","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1159\/000049053","volume":"90","author":"P Kotanko","year":"2002","unstructured":"Kotanko P, Kirisits W, Skrabal F (2002) Rhabdomyolysis and acute renal graft impairment in a patient treated with simvastatin, tacrolimus, and fusidic acid. Nephron 90(2):234\u2013235","journal-title":"Nephron"},{"issue":"4","key":"3768_CR33","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s40256-020-00421-1","volume":"20","author":"YN Lamb","year":"2020","unstructured":"Lamb YN (2020) Rosuvastatin\/ezetimibe: a review in hypercholesterolemia. Am J Cardiovasc Drugs 20(4):381\u2013392","journal-title":"Am J Cardiovasc Drugs"},{"issue":"9","key":"3768_CR34","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1111\/j.1600-6143.2005.01005.x","volume":"5","author":"WP Lemahieu","year":"2005","unstructured":"Lemahieu WP, Hermann M, Asberg A et al (2005) Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus. Am J Transplant 5(9):2236\u20132243","journal-title":"Am J Transplant"},{"key":"3768_CR35","unstructured":"LiverTox: Clinical and research information on drug-induced liver injury\u00a0(2012) National Institute of diabetes and digestive and kidney diseases."},{"issue":"11","key":"3768_CR36","doi-asserted-by":"publisher","first-page":"2822","DOI":"10.1016\/S0149-2918(03)80336-3","volume":"25","author":"PD Martin","year":"2003","unstructured":"Martin PD, Warwick MJ, Dane AL et al (2003) Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clin Ther 25(11):2822\u20132835","journal-title":"Clin Ther"},{"key":"3768_CR37","doi-asserted-by":"publisher","first-page":"S93","DOI":"10.1016\/j.ihj.2024.01.004","volume":"76","author":"A Mehta","year":"2024","unstructured":"Mehta A (2024) Managing dyslipidemia in solid organ transplant patients. Indian Heart J 76:S93\u2013S95","journal-title":"Indian Heart J"},{"issue":"2","key":"3768_CR38","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1177\/1060028019871891","volume":"54","author":"DR Migliozzi","year":"2020","unstructured":"Migliozzi DR (2020) Clinical controversy in transplantation: tacrolimus versus cyclosporine in statin drug interactions. Ann Pharmacother 54(2):171\u2013177","journal-title":"Ann Pharmacother"},{"issue":"1","key":"3768_CR39","doi-asserted-by":"publisher","first-page":"e007480","DOI":"10.1161\/CIRCOUTCOMES.120.007480","volume":"14","author":"J Moon","year":"2021","unstructured":"Moon J, Cohen Sedgh R, Jackevicius CA (2021) Examining the nocebo effect of statins through statin adverse events reported in the food and drug administration adverse event reporting system. Circ Cardiovasc Qual Outcomes 14(1):e007480","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"3768_CR40","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1080\/00498250210144820","volume":"32","author":"K Nezasa","year":"2002","unstructured":"Nezasa K, Takao A, Kimura K et al (2002) Pharmacokinetics and disposition of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in rat. Xenobiotica 32:715\u2013727","journal-title":"Xenobiotica"},{"key":"3768_CR41","doi-asserted-by":"publisher","first-page":"715577","DOI":"10.3389\/fphar.2021.715577","volume":"12","author":"C Ning","year":"2021","unstructured":"Ning C, Su S, Li J et al (2021) Evaluation of a clinically relevant drug-drug interaction between rosuvastatin and clopidogrel and the risk of hepatotoxicity. Front Pharmacol 12:715577","journal-title":"Front Pharmacol"},{"issue":"1","key":"3768_CR42","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1248\/yakushi.127.209","volume":"127","author":"T Niwa","year":"2007","unstructured":"Niwa T, Yamamoto S, Saito M et al (2007) Effect of cyclosporine and tacrolimus on cytochrome p450 activities in human liver microsomes. Yakugaku Zasshi 127(1):209\u2013216","journal-title":"Yakugaku Zasshi"},{"key":"3768_CR43","doi-asserted-by":"publisher","first-page":"101762","DOI":"10.1016\/j.bpg.2021.101762","volume":"54\u201355","author":"J Noble","year":"2021","unstructured":"Noble J, Terrec F, Malvezzi P et al (2021) Adverse effects of immunosuppression after liver transplantation. Best Pract Res Clin Gastroenterol 54\u201355:101762","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"3","key":"3768_CR44","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/jcdd8030024","volume":"8","author":"H Nomani","year":"2021","unstructured":"Nomani H, Mohammadpour AH, Reiner \u017d et al (2021) Statin therapy in post-operative atrial fibrillation: focus on the anti-inflammatory effects. JCDD 8(3):24","journal-title":"JCDD"},{"issue":"9","key":"3768_CR45","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s40262-013-0069-2","volume":"52","author":"K Ogasawara","year":"2013","unstructured":"Ogasawara K, Chitnis SD, Gohh RY, Christians U (2013) Multidrug resistance-associated protein 2 (MRP2\/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients. Clin Pharmacokinet 52(9):751\u2013762","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"3768_CR46","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1097\/TP.0000000000003350","volume":"105","author":"SC Ong","year":"2021","unstructured":"Ong SC, Gaston RS (2021) Thirty years of tacrolimus in clinical practice. Transplantation 105(3):484\u2013495","journal-title":"Transplantation"},{"issue":"7","key":"3768_CR47","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1124\/dmd.119.086496","volume":"47","author":"A Parkinson","year":"2019","unstructured":"Parkinson A (2019) Regulatory recommendations for calculating the unbound maximum hepatic inlet concentration: a complicated story with a surprising and happy ending. Drug Metab Dispos 47(7):779\u2013784","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"3768_CR48","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/bmc.1305","volume":"24","author":"XL Qin","year":"2010","unstructured":"Qin XL, Bi HC, Wang CX, Li JL, Wang XD, Liu LS, Chen X, Huang M (2010) Study of the effect of Wuzhi tablet (Schisandra sphenanthera extract) on tacrolimus tissue distribution in rat by liquid chromatography tandem mass spectrometry method. Biomed Chromatogr 24(4):399\u2013405","journal-title":"Biomed Chromatogr"},{"issue":"12","key":"3768_CR49","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.3390\/jpm13121706","volume":"13","author":"L Rostaing","year":"2023","unstructured":"Rostaing L, Jouve T, Terrec F et al (2023) Adverse drug events after kidney transplantation. J Pers Med 13(12):1706","journal-title":"J Pers Med"},{"issue":"2","key":"3768_CR50","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/1744-9987.13748","volume":"26","author":"Z Sablji\u0107","year":"2022","unstructured":"Sablji\u0107 Z, Ba\u0161i\u0107-Juki\u0107 N (2022) Toxic myopathy and liver damage caused by concomitant therapy with remdesivir, atorvastatin, ezetimibe, and tacrolimus in a renal transplant patient with recently treated SARS-CoV-2 induced pneumonia: a case report. Ther Apher Dial 26(2):478\u2013479","journal-title":"Ther Apher Dial"},{"issue":"3","key":"3768_CR51","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1124\/jpet.105.099036","volume":"317","author":"H Saito","year":"2006","unstructured":"Saito H, Hirano H, Nakagawa H et al (2006) A new strategy of high-speed screening and quantitative structure-activity relationship analysis to evaluate human ATP-binding cassette transporter ABCG2-drug interactions. J Pharmacol Exp Ther 317(3):1114\u20131124","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"3768_CR52","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/0006-2952(94)90136-8","volume":"47","author":"T Shiraga","year":"1994","unstructured":"Shiraga T, Matsuda H, Nagase K, Iwasaki K, Noda K, Yamazaki H, Shimada T, Funae Y (1994) Metabolism of FK506, a potent immunosuppressive agent, by cytochrome P450 3A enzymes in rat, dog and human liver microsomes. Biochem Pharmacol 47(4):727\u2013735","journal-title":"Biochem Pharmacol"},{"key":"3768_CR53","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/S1567-5688(01)80227-0","volume":"2","author":"E Stein","year":"2001","unstructured":"Stein E, Strutt KL, Miller E (2001) Southworth H. Rosuvastatin (20, 40 and 80 MG) reduces LDL-C, raises HDL-C and achieves treatment goals more effectively than atorvastatin (20, 40 and 80 MG) in patients with heterozygous familial hypercholesterolaemia. Atheroscler Suppl 2:90\u201391","journal-title":"Atheroscler Suppl"},{"issue":"6","key":"3768_CR54","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.tiv.2014.05.016","volume":"28","author":"M Szab\u00f3","year":"2014","unstructured":"Szab\u00f3 M, Veres Z, B\u00e1tai-Konczos A et al (2014) Statins alter the hepatobiliary transport of unconjugated and conjugated bilirubin in sandwich-cultured rat hepatocytes. Toxicol in Vitro 28(6):1136\u20131143","journal-title":"Toxicol in Vitro"},{"issue":"7","key":"3768_CR55","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.3390\/jcm9072193","volume":"9","author":"C Thongprayoon","year":"2020","unstructured":"Thongprayoon C, Hansrivijit P, Kovvuru K et al (2020) Impacts of high intra- and inter-individual variability in tacrolimus pharmacokinetics and fast tacrolimus metabolism on outcomes of solid organ transplant recipients. JCM 9(7):2193","journal-title":"JCM"},{"key":"3768_CR56","unstructured":"U.S. Department (2020). \u201cU.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). In Vitro Drug Interaction Studies\u2014Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions Guidance for Industry (MD: Silver Spring)"},{"key":"3768_CR57","unstructured":"U.S. Department (2020). \"U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Clinical Drug Interaction Studies \u2014 Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions Guidance for Industry (MD: Silver Spring)"},{"issue":"10","key":"3768_CR58","doi-asserted-by":"publisher","first-page":"707","DOI":"10.2165\/00002018-200225100-00003","volume":"25","author":"T van Gelder","year":"2002","unstructured":"van Gelder T (2002) Drug interactions with tacrolimus. Drug Saf 25(10):707\u2013712","journal-title":"Drug Saf"},{"issue":"5","key":"3768_CR59","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.tiv.2015.04.013","volume":"29","author":"R Vrzal","year":"2015","unstructured":"Vrzal R, Zenata O, Bachleda P et al (2015) The effects of drugs with immunosuppressive or immunomodulatory activities on xenobiotics-metabolizing enzymes expression in primary human hepatocytes. Toxicol in Vitro 29(5):1088\u20131099","journal-title":"Toxicol in Vitro"},{"issue":"12","key":"3768_CR60","doi-asserted-by":"publisher","first-page":"e121","DOI":"10.1161\/CIRCRESAHA.119.315233","volume":"124","author":"NC Ward","year":"2019","unstructured":"Ward NC, Watts GF, Eckel RH (2019) Response by Ward et al to Letter Regarding Article, \u201cStatin toxicity: mechanistic insights and clinical implications.\u201d Circ Res 124(12):e121\u2013e122","journal-title":"Circ Res"},{"issue":"2","key":"3768_CR61","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jacl.2019.01.011","volume":"13","author":"BA Warden","year":"2019","unstructured":"Warden BA, Duell PB (2019) Management of dyslipidemia in adult solid organ transplant recipients. J Clin Lipidol 13(2):231\u2013245","journal-title":"J Clin Lipidol"},{"issue":"21","key":"3768_CR62","doi-asserted-by":"publisher","first-page":"e468","DOI":"10.1161\/CIR.0000000000000456","volume":"134","author":"BS Wiggins","year":"2016","unstructured":"Wiggins BS, Saseen JJ, Page RL et al (2016) Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the american heart association. Circulation 134(21):e468\u2013e495","journal-title":"Circulation"},{"issue":"5","key":"3768_CR63","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1002\/(SICI)1099-081X(199807)19:5<279::AID-BDD101>3.0.CO;2-Q","volume":"19","author":"H Yamada","year":"1998","unstructured":"Yamada H, Kotaki H, Sawada Y, Iga T (1998) Simvastatin-tacrolimus and simvastatin-cyclosporin interactions in rats. Biopharm Drug Dispos 19(5):279\u2013284","journal-title":"Biopharm Drug Dispos"},{"issue":"6","key":"3768_CR64","doi-asserted-by":"publisher","first-page":"513","DOI":"10.2174\/1389200219666180129151948","volume":"19","author":"M Yu","year":"2018","unstructured":"Yu M, Liu M, Zhang W, Ming Y (2018) Pharmacokinetics, pharmacodynamics and pharmacogenetics of tacrolimus in kidney transplantation. Curr Drug Metab 19(6):513\u2013522","journal-title":"Curr Drug Metab"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-024-03768-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-024-03768-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-024-03768-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T05:27:00Z","timestamp":1757136420000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-024-03768-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,25]]},"references-count":64,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["3768"],"URL":"https:\/\/doi.org\/10.1007\/s00210-024-03768-3","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"type":"print","value":"0028-1298"},{"type":"electronic","value":"1432-1912"}],"subject":[],"published":{"date-parts":[[2025,1,25]]},"assertion":[{"value":"23 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The experiments were conducted in accordance with the National Institutes of Health (NIH) guidelines for the care and use of laboratory animals. This study was approved by the Institutional Animal Care and Use Committee of the Second Affiliated Hospital of Nanchang University in 2016 (Permit Number: No. [2016]097). This study was carried out in compliance with the ARRIVE guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}